Toungouz-Névessignsky M, Andrien M, Dupont E
Département d'Immunologie, Hématologie et Transfusion, Hôpital Erasme, Bruxelles.
Rev Med Brux. 1992 May;13(5):152, 155-9.
In the last twenty years bone marrow transplantation has become the treatment of choice for many hematological malignancies and immunologic defects. The ideal donor is a perfectly HLA-identical family member. Given the limited proportion of patients who can benefit of such a donor, unrelated bone marrow donors are increasingly being used. The immunological methods of selection used for siblings have been shown to be inadequate for the new type of donors. New techniques of molecular biology detecting a new micropolymorphism have been developed. This paper discusses the techniques and interpretations of the immunological tests of selection.
在过去二十年中,骨髓移植已成为许多血液系统恶性肿瘤和免疫缺陷疾病的首选治疗方法。理想的供体是人类白细胞抗原(HLA)完全匹配的家庭成员。鉴于能够受益于此类供体的患者比例有限,越来越多地使用非亲属骨髓供体。事实证明,用于同胞供体选择的免疫方法不适用于新型供体。已经开发出检测新的微多态性的分子生物学新技术。本文讨论了选择免疫测试的技术和解释。